标题
Advanced gastric cancer: Current treatment landscape and future perspectives
作者
关键词
-
出版物
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 22, Issue 8, Pages 2403
出版商
Baishideng Publishing Group Inc.
发表日期
2016-03-01
DOI
10.3748/wjg.v22.i8.2403
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
- (2015) M Zhu et al. BRITISH JOURNAL OF CANCER
- Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer
- (2015) Clarinda Chua et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
- (2015) Min-Hee Ryu et al. EUROPEAN JOURNAL OF CANCER
- Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
- (2014) Y. Yamada et al. ANNALS OF ONCOLOGY
- Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
- (2014) Y-K Kang et al. BRITISH JOURNAL OF CANCER
- Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)
- (2014) Katsuhiko Higuchi et al. EUROPEAN JOURNAL OF CANCER
- Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
- (2014) Taroh Satoh et al. Gastric Cancer
- Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
- (2014) Rosine Guimbaud et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer
- (2014) C. Kim et al. ONCOLOGIST
- Quality of Life in the Trastuzumab for Gastric Cancer Trial
- (2014) Taroh Satoh et al. ONCOLOGIST
- Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis
- (2013) H. S. Kim et al. ANNALS OF ONCOLOGY
- Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
- (2013) S Lorenzen et al. BRITISH JOURNAL OF CANCER
- Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
- (2013) Wasaburo Koizumi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
- (2013) Shuichi Hironaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
- (2012) Salah-Eddin Al-Batran et al. EUROPEAN JOURNAL OF CANCER
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
- (2012) R. Pirker et al. LUNG CANCER
- Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
- (2011) Y. Yamashita-Kashima et al. CLINICAL CANCER RESEARCH
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
- (2010) Jaffer A. Ajani et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
- (2009) M. Moehler et al. ANNALS OF ONCOLOGY
- Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
- (2009) Y.-K. Kang et al. ANNALS OF ONCOLOGY
- Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
- (2009) Narikazu Boku et al. LANCET ONCOLOGY
- Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer
- (2008) B. Paul et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
- (2008) M. Dank et al. ANNALS OF ONCOLOGY
- Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
- (2008) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started